Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

This study found that while infectious events may occur in alopecia areata patients treated with JAK inhibitors, these infections are usually manageable and rarely lead to permanent treatment discontinuation.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

This narrative review reports that Janus kinase inhibitors show promise as an effective treatment for alopecia areata, especially in patients who do not respond to conventional therapies, although further research on long-term use and topical application is needed.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This study demonstrated that an ethanol extract of Connarus semidecandrus Jack showed potential anti-androgenic alopecia effects in a testosterone-induced model, suggesting a possible treatment option for hair loss.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.

This literature watch compiles recent studies on photobiomodulation therapy across various applications, offering no new empirical findings.

This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

This case report suggests that starting selective Janus kinase 1 inhibition may improve alopecia in a patient with rheumatoid arthritis who was not responding to TNF-α inhibitor therapy and corticosteroids.

This narrative review highlights the potential of naturally occurring compounds to target specific molecular pathways and overcome resistance in advanced and recurrent papillary thyroid cancer, offering new therapeutic possibilities beyond traditional treatments like surgery and lifelong hormone replacement.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

In this study of women with frontal fibrosing alopecia, delgocitinib cream improved the molecular signature of lesions and demonstrated potential as a treatment, showing significant transcriptomic changes and some clinical improvements over 12 weeks compared to a cream vehicle.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This review analyzed recent studies and concluded that JAK inhibitors are effective for treating lichen planopilaris, though concerns about long-term safety remain and further research is needed.

In this study, JAUN soap was found to improve skin conditions, such as moisture, elasticity, and cleansing effectiveness, without adverse reactions, suggesting its potential as a safe and effective ingredient for functional cosmetics.

In this case study, researchers reported that using Raktamokshana therapy through leech application led to symptom relief in a 5-year-old girl with alopecia areata after eight sessions, suggesting this Ayurvedic treatment may be beneficial for children with similar conditions.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

In this true experimental study, researchers assessed the antibacterial effect of white jasmine leaf extract against Propionibacterium acnes and found varying inhibition zone diameters, with 500 µg/mL achieving up to 10.95 mm, though less effective than clindamycin, which reached 28.55 mm.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

In this study, a gel containing extracts from Coffea arabica and Larrea divaricata was found to significantly thicken eyebrows and eyelashes in most premenopausal and postmenopausal women, without causing adverse effects, but showed no statistical difference from a placebo in overall hair growth.